
    
      The standard or usual treatment for this disease is pembrolizumab given by needle every three
      weeks. This study will be done in two stages.

      The purpose of stage 1 of the study is to find out if we can use blood tests to see how the
      cancer is responding to treatment with pembrolizumab. A second stage of the study will take
      place once stage 1 is completed. In stage 2 blood tests will be used to help determine if
      patients whose cancer does not seem to be getting better on treatment with pembrolizumab,
      would do better on a different treatment.
    
  